Zomedica Corp Stock Price, News & Analysis

Zomedica (OTCQB:ZOMDF) has expanded its distribution agreement with UXR Inc. to strengthen its presence in the Canadian veterinary market. Under the agreement, UXR becomes the exclusive distributor of Zomedica's PulseVet® system and VETGuardian® products in Canada, along with distribution rights for the Assisi® product portfolio.

The expansion targets a market of over 4,000 veterinary practices in Canada, with a projected 7% compound annual growth rate. The partnership aims to enhance access to Zomedica's innovative therapeutic and monitoring solutions for the country's 28 million pets, focusing on technologies that reduce pain, improve recovery, and enhance monitoring in veterinary practices.

Zomedica (OTCQB:ZOMDF) has announced a strategic distribution partnership with Pioneer Veterinary Products Limited to strengthen its presence in the UK veterinary market. The agreement initially focuses on distributing Zomedica's TRUFORMA® diagnostic platform across England, Scotland, Wales, and Northern Ireland, with plans to later introduce VETGuardian® remote monitoring technology.

Pioneer will serve as an exclusive distributor for the small animal market and a non-exclusive distributor for equine products. The TRUFORMA platform provides reference lab-quality results for diagnosing endocrine and thyroid conditions in dogs, cats, and horses, while VETGuardian offers wireless, contactless monitoring of animal vitals in surgical and post-operative care settings.

Zomedica (OTCQB:ZOMDF) has announced a strategic two-year partnership with VerticalVet, a major veterinary Group Purchasing Organization serving over 2,600 independent practices across the United States. Through this collaboration, VerticalVet members will receive preferred access to Zomedica's advanced veterinary technologies.

The partnership includes access to several key technologies: the PulseVet® shock wave therapy system for healing and pain management, VETGuardian® remote monitoring platform, Assisi® targeted pulsed electromagnetic field therapy devices, and Vetigel® hemostatic gel for surgical bleeding control.

Zomedica (OTCQB:ZOMDF) announced its upcoming Fourth Friday at Four webinar on August 22, 2025, focusing on their VETIGEL® hemostatic gel product. The webinar, scheduled for 4:00 PM ET, will showcase this plant-based solution designed for rapid bleeding control in veterinary medicine.

VETIGEL® offers veterinary professionals a quick and efficient method for managing soft tissue and superficial wounds through its syringe-based delivery system. The product accelerates clot formation and seals wounds, eliminating the need for traditional methods like manual pressure or cautery. The webinar will feature clinical case studies, real-world outcomes, and testimonials from veterinary professionals, followed by a live Q&A session with Zomedica's product and commercial leaders.

Zomedica (OTCQB:ZOMDF), a veterinary health company, reported strong Q2 2025 financial results with revenue growing 14% to $7.0 million, marking its 18th consecutive quarter of year-over-year growth. The company achieved 67% gross margins and maintained a robust liquidity position of $59.1 million.

Key highlights include 86% growth in the Diagnostics segment, primarily driven by TRUFORMA platform adoption, and 21% growth in Consumable sales to $5.3 million. The Therapeutic Device segment, comprising PulseVet and Assisi products, grew 8% to $6.2 million. International sales increased by 13% year-over-year. Operating expenses decreased by $0.7 million, though the company reported a net loss of $7.4 million.

Zomedica (OTCQB:ZOMDF) announces its upcoming Fourth Friday at Four webinar on July 25, 2025, focusing on their Assisi product line of targeted Pulsed Electromagnetic Field (tPEMF) therapy devices. The webinar will showcase their drug-free solutions including the Assisi Loop®, Assisi Loop Lounge®, and Calmer Canine® products.

The session will feature insights into tPEMF technology, clinical outcomes, and real-world applications in veterinary care. Led by Nicole Westfall, Senior VP of Marketing, and Mialisa Gluckert, Senior Director of Assisi Commercialization, the webinar will demonstrate how these non-invasive treatments are revolutionizing pain and inflammation management in companion animals.

Zomedica (OTCQB:ZOMDF) has announced a strategic sponsorship agreement between its PulseVet shock wave device and the World Equestrian Center - Ocala (WEC), establishing PulseVet as the official shock wave therapy provider at the venue. The partnership includes comprehensive brand visibility through arena signage, digital promotions, and features in WEC publications.

The collaboration aims to enhance veterinary care for elite equine athletes by providing non-invasive shock wave therapy for musculoskeletal injuries. The agreement includes on-site educational resources, promotional materials, and hospitality privileges during WEC events, including discounted lodging and VIP access.

Zomedica (OTCQB:ZOMDF) has been granted a new U.S. Patent (No. 12,299,917 B2) for its TRUVIEW microscope, specifically covering Methods and Systems for Slide Imaging Calibration. The patent strengthens the company's intellectual property portfolio, which now comprises 77 U.S. patents, 144 international patents, 33 U.S. trademarks, and 107 foreign trademarks.

Bill Campbell, VP of Imaging Systems and TRUVIEW's inventor, emphasized the patent's significance in validating their focusing system innovation. CEO Larry Heaton highlighted how this protection enables continued investment in market expansion while maintaining product uniqueness.

Zomedica Corp. (ZOM) has announced its upcoming Fourth Friday at Four webinar, scheduled for June 27, 2025, at 4:00 PM ET. The webinar will focus on the company's TRUFORMA diagnostic platform, an in-clinic system designed for point-of-care veterinary diagnostics. The TRUFORMA system enables veterinarians to perform precise, rapid, and reliable testing without relying on external labs. The webinar will include platform demonstrations, expert insights on diagnostic workflow transformation, case studies of improved patient outcomes, and an interactive Q&A session with Zomedica's leadership and technical experts. CEO Larry Heaton emphasizes the company's commitment to empowering veterinarians with tools that enhance diagnostic capabilities while improving practice efficiency and profitability.